Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy

Table 2 Receiver operating characteristic analysis of all biomarkers for predicting response to pulmonary artery catheter guided therapy.

Biomarker	AUC	95% CI	P
CVP non-response ^a
sST2	0.82	(0.66 - 0.98)	< 0.001
NT-proBNP	0.64	(0.42 - 0.85)	0.10
hsTnI	0.56	(0.34 - 0.77)	0.30
eTnI	0.51	(0.29 - 0.74)	0.45
cys-C	0.70	(0.51 - 0.90)	0.02
MPO	0.48	(0.24 - 0.72)	0.57
PCWP non-response ^b
sST2	0.68	(0.45 - 0.91)	0.06
NT-proBNP	0.63	(0.40 - 0.86)	0.13
hsTnI	0.53	(0.31 - 0.74)	0.41
eTnI	0.52	(0.29 - 0.74)	0.44
cys-C	0.62	(0.37 - 0.87)	0.18
MPO	0.52	(0.31 - 0.74)	0.42
SVR non-responsec
sST2	0.59	(0.38 - 0.80)	0.19
NT-proBNP	0.69	(0.48 - 0.89)	0.04
hsTnI	0.40	(0.19 - 0.61)	0.82
eTnI	0.39	(0.17 - 0.61)	0.84
cys-C	0.45	(0.23 - 0.67)	0.67
MPO	0.39	(0.18 - 0.60)	0.85

^aAUC for CVP non-response was significantly higher for sST2 as compared to cTnI (P = 0.03), and eTnI (P = 0.02), no significant difference between AUC for sST2 and cys-C/NT-proBNP/MPO; ^bNo significant difference among AUCs for PCWP non-response; ^cNo significant difference among AUCs for SVR non-response. AUC, area under the curve; CI, confidence intervals; cys-C, cystatin C; eTnI, experimental research prototype Troponin I; hsTnI, highly sensitive Troponin I; MPO, myeloperoxidase; NT-proBNP, amino terminal cleavage fragment of B-type natriuretic peptide; sST2, soluble ST2.

ISSN: 1364-8535